

Frances Boyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8999344/publications.pdf>

Version: 2024-02-01

37
papers

1,395
citations

567281

15
h-index

345221

36
g-index

37
all docs

37
docs citations

37
times ranked

2620
citing authors

#	ARTICLE	IF	CITATIONS
1	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology</i> , The, 2014, 15, 1137-1146.	10.7	382
2	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 88-96.	10.7	128
3	Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 217-225.	1.6	118
4	A systematic review of decision aids for patients making a decision about treatment for early breast cancer. <i>Breast</i> , 2016, 26, 31-45.	2.2	104
5	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	6.3	73
6	The Effect of Mobile App Interventions on Influencing Healthy Maternal Behavior and Improving Perinatal Health Outcomes: Systematic Review. <i>JMIR MHealth and UHealth</i> , 2018, 6, e10012.	3.7	63
7	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Supportive Care in Cancer</i> , 2017, 25, 3485-3493.	2.2	59
8	Survival outcomes of the NeoALTTO study (BIG 1â€™06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	2.8	51
9	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , 2017, 128, 1166-1175.	1.5	50
10	Patient-reported quality of life, unmet needs and care coordination outcomes: Moving toward targeted breast cancer survivorship care planning. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e323-e331.	1.1	40
11	Acupuncture for Aromatase Inhibitorâ€™Induced Arthralgia. <i>Integrative Cancer Therapies</i> , 2015, 14, 496-502.	2.0	37
12	Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?. <i>SpringerPlus</i> , 2014, 3, 282.	1.2	36
13	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (Tâ€™L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 1BA4-1BA4.	1.6	32
14	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. <i>Breast Cancer Research</i> , 2015, 17, 56.	5.0	30
15	VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors â€™ Efficacy, Safety, and Biomarker Results. <i>Clinical Cancer Research</i> , 2022, 28, 3256-3267.	7.0	28
16	A systematic literature review of attitudes towards secondary use and sharing of health administrative and clinical trial data: a focus on consent. <i>Systematic Reviews</i> , 2021, 10, 132.	5.3	23
17	A systematic literature review of health consumer attitudes towards secondary use and sharing of health administrative and clinical trial data: a focus on privacy, trust, and transparency. <i>Systematic Reviews</i> , 2020, 9, 235.	5.3	21
18	The FACT-Melanoma Quality-of-Life Instrument. <i>Melanoma Research</i> , 2013, 23, 61-69.	1.2	12

#	ARTICLE	IF	CITATIONS
19	A Case of Opioid Toxicity on Conversion From Extended-Release Oxycodone and Naloxone to Extended-Release Oxycodone in a Patient With Liver Dysfunction. <i>Journal of Pain and Symptom Management</i> , 2017, 53, e1-e2.	1.2	12
20	A systematic literature review of researchers'™ and healthcare professionals'™ attitudes towards the secondary use and sharing of health administrative and clinical trial data. <i>Systematic Reviews</i> , 2020, 9, 240.	5.3	12
21	Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study. <i>Quality of Life Research</i> , 2020, 29, 2021-2027.	3.1	11
22	Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients. <i>Familial Cancer</i> , 2022, 21, 157-166.	1.9	9
23	The social meanings of choice in living-with advanced breast cancer. <i>Social Science and Medicine</i> , 2021, 280, 114047.	3.8	8
24	The role of breast reconstruction choice on body image patient-reported outcomes at four years post-mastectomy for breast cancer: A longitudinal prospective cohort study. <i>Psycho-Oncology</i> , 2022, 31, 54-61.	2.3	8
25	Development of the Melanoma Concerns Questionnaire (MCQ [®] 28); refinement of the EORTC QLQ [®] MEL38 module. <i>Psycho-Oncology</i> , 2020, 29, 321-330.	2.3	7
26	A Decision Aid for Women Considering Neoadjuvant Systemic Therapy for Operable Invasive Breast Cancer: Development and Protocol of a Phase II Evaluation Study (ANZ1301 DOMINO). <i>JMIR Research Protocols</i> , 2016, 5, e88.	1.0	7
27	Accreditation Standard Guideline Initiative for Tai Chi and Qigong Instructors and Training Institutions. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 51.	1.4	6
28	Switching between endocrine therapies for primary breast cancer: Frequency and timing in Australian clinical practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e161-e170.	1.1	5
29	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , 2016, 56, 85-92.	2.8	4
30	Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 3-11.	1.1	4
31	Breast cancer recurrence following active treatment: determining its incidence in the NSW population. <i>Public Health Research and Practice</i> , 2016, 26, e2611607.	1.5	4
32	<i>eTRIO</i> trial: study protocol of a randomised controlled trial of online education modules to facilitate effective family caregiver involvement in oncology. <i>BMJ Open</i> , 2021, 11, e043224.	1.9	3
33	Perinatal outcomes of women with gestational breast cancer in Australia and New Zealand: A prospective population-based study. <i>Birth</i> , 2022, 49, 763-773.	2.2	3
34	Screening and Audit as Service-Level Strategies to Support Implementation of Australian Guidelines for Cancer Pain Management in Adults: A Feasibility Study. <i>Pain Management Nursing</i> , 2019, 20, 113-117.	0.9	2
35	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2022, 30, 5965-5974.	2.2	2
36	Clinical Decision Making in the Management of Breast Cancer Diagnosed During Pregnancy: A Review and Case Series Analysis. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, , .	1.3	1

#	ARTICLE	IF	CITATIONS
37	Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer. Public Health Research and Practice, 2017, 27, .	1.5	0